Expression Profiles of MYC Protein and MYC Gene Rearrangement in Lymphomas
Authors:
- Karen M. ChisholmKCKaren M. Chisholm
- Charles D. BangsCBCharles D. Bangs
- Carlos E. BacchiCBCarlos E. Bacchi
- Hernan Molina- KirschHKHernan Molina- Kirsch
- Athena CherryACAthena Cherry
- Yasodha NatkunamYNYasodha Natkunam
- 1 March 2015
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 39 (3) , 294-303
Abstract
MYC translocations are a defining feature of Burkitt lymphoma and a group of diffuse large B-cell lymphoma (DLBCL) with inferior outcome. However, the clinical relevance of MYC gene rearrangement and its relationship with MYC protein expression has not been well characterized in lymphomas. Tissue microarrays containing 1214 lymphomas were successfully evaluated by immunohistochemistry using anti-MYC clone Y69 and a dual-color break-apart fluorescence in situ hybridization probe to detect MYC gene rearrangements. Aggressive B-cell lymphomas including Burkitt lymphoma and DLBCL showed the highest level of MYC protein staining defined as staining in >50% of lymphoma cells. A significant proportion of plasmablastic, B-lymphoblastic and T-lymphoblastic, and extranodal NK/T-cell lymphomas also showed staining in >50% of cells, whereas only occasional plasma cell myeloma, mantle cell lymphoma, and classical Hodgkin lymphoma showed a high level of staining. Small B-cell lymphomas, when positive, showed MYC protein in <50% of cells. In aggressive B-cell lymphomas, MYC rearrangement and MYC immunohistochemistry showed a high concordance rate; however, some DLBCL and all T-cell and NK-cell lymphomas with MYC protein expression lacked MYC gene rearrangements. Our results provide a baseline for MYC protein expression in lymphomas and indicate that its expression is not specific to lymphoma subtypes, cell lineage, or expected clinical behavior and is highly variable. In addition, MYC protein expression is not necessarily correlated with MYC gene rearrangements and suggests the need for caution in the interpretation of MYC immunohistochemistry in the differential diagnosis of lymphomas.Keywords
This publication has 45 references indexed in Scilit:
- Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classificationBlood, 2013
- MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphomaBlood, 2013
- Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneJournal of Clinical Oncology, 2012
- Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell LymphomasPLOS ONE, 2012
- Burkitt's lymphomaThe Lancet, 2012
- The impact of MYC expression in lymphoma biology: Beyond Burkitt lymphomaBlood Cells, Molecules, and Diseases, 2010
- The c-Myc target gene networkSeminars in Cancer Biology, 2006
- c-Myc-regulated microRNAs modulate E2F1 expressionNature, 2005
- c-MYC: more than just a matter of life and deathNature Reviews Cancer, 2002
- Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell LymphomaBlood, 1998